As the Innovation Act passes out of committee patent reform still lacks key industry support 12 Jun 15
Like its Senate counterpart last week, the Innovation Act comfortably passed out of committee yesterday after mark-up by the House Judiciary Committee. It did so, however, with notable concerns yet to be resolved. In separate statements the Biotechnology Industry Organization (BIO), the Pharmaceutical Research and Manufacturers of America (PhRMA) and the National Venture Capital Association (NVCA) all made plain their opposition to the amended bill. That means that neither bill has won the kind of broad industry support that is normally vital in moving legislation to a vote in both chambers of Congress.
Want to read more?
Register to access two of our subscriber-only articles per month
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts
What our customers are saying
IAM is the only publication that places a business focus on intellectual property. Readers are given real insight into, and guidance on, managing intellectual property as a true business asset.
Reed Smith LLP
Subscribe to receive access to the full range of premium business intelligence, insights and analysis, as well as our IP directories, guides and daily news.
Register for more free content
- Read more IAM blogs and articles
- Receive the editor's weekly review by email